Brandon Couillard
Stock Analyst at Wells Fargo
(4.32)
# 357
Out of 4,853 analysts
124
Total ratings
57.65%
Success rate
13.99%
Average return
Main Sectors:
Stocks Rated by Brandon Couillard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MLAB Mesa Laboratories | Maintains: Underweight | $120 → $100 | $99.50 | +0.50% | 2 | May 30, 2025 | |
| TECH Bio-Techne | Initiates: Overweight | $59 | $48.31 | +22.13% | 1 | May 30, 2025 | |
| MYGN Myriad Genetics | Downgrades: Equal-Weight | $22 → $6 | $4.92 | +21.95% | 2 | May 8, 2025 | |
| MTD Mettler-Toledo International | Maintains: Equal-Weight | $1,125 → $1,200 | $1,164.61 | +3.04% | 5 | May 5, 2025 | |
| WGS GeneDx Holdings | Maintains: Equal-Weight | $105 → $78 | $69.17 | +12.77% | 3 | May 1, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $580 → $570 | $398.36 | +43.09% | 5 | Apr 24, 2025 | |
| A Agilent Technologies | Maintains: Hold | $135 → $116 | $113.94 | +1.81% | 22 | Apr 21, 2025 | |
| RVTY Revvity | Maintains: Equal-Weight | $130 → $102 | $90.50 | +12.71% | 2 | Apr 17, 2025 | |
| BRKR Bruker | Maintains: Overweight | $75 → $60 | $37.69 | +59.19% | 3 | Apr 17, 2025 | |
| BIO Bio-Rad Laboratories | Maintains: Equal-Weight | $320 → $270 | $219.31 | +23.11% | 9 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $320 → $270 | $231.40 | +16.68% | 9 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $22 | $12.95 | +69.88% | 4 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $415 → $420 | $346.33 | +21.27% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $280 → $240 | $192.15 | +24.90% | 2 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $285 → $260 | $180.26 | +44.24% | 11 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $77 → $80 | $70.41 | +13.62% | 6 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $28 → $24 | $18.77 | +27.90% | 2 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $85 | $54.38 | +56.31% | 16 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $126.68 | +42.09% | 1 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $2.17 | +360.83% | 1 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $30 → $23 | $18.68 | +23.13% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $0.74 | +1,652.02% | 1 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.81 | - | 11 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $11 | $2.26 | +386.73% | 2 | Oct 13, 2017 |
Mesa Laboratories
May 30, 2025
Maintains: Underweight
Price Target: $120 → $100
Current: $99.50
Upside: +0.50%
Bio-Techne
May 30, 2025
Initiates: Overweight
Price Target: $59
Current: $48.31
Upside: +22.13%
Myriad Genetics
May 8, 2025
Downgrades: Equal-Weight
Price Target: $22 → $6
Current: $4.92
Upside: +21.95%
Mettler-Toledo International
May 5, 2025
Maintains: Equal-Weight
Price Target: $1,125 → $1,200
Current: $1,164.61
Upside: +3.04%
GeneDx Holdings
May 1, 2025
Maintains: Equal-Weight
Price Target: $105 → $78
Current: $69.17
Upside: +12.77%
Thermo Fisher Scientific
Apr 24, 2025
Maintains: Overweight
Price Target: $580 → $570
Current: $398.36
Upside: +43.09%
Agilent Technologies
Apr 21, 2025
Maintains: Hold
Price Target: $135 → $116
Current: $113.94
Upside: +1.81%
Revvity
Apr 17, 2025
Maintains: Equal-Weight
Price Target: $130 → $102
Current: $90.50
Upside: +12.71%
Bruker
Apr 17, 2025
Maintains: Overweight
Price Target: $75 → $60
Current: $37.69
Upside: +59.19%
Bio-Rad Laboratories
Apr 17, 2025
Maintains: Equal-Weight
Price Target: $320 → $270
Current: $219.31
Upside: +23.11%
Apr 17, 2025
Maintains: Equal-Weight
Price Target: $320 → $270
Current: $231.40
Upside: +16.68%
Apr 17, 2025
Maintains: Overweight
Price Target: $25 → $22
Current: $12.95
Upside: +69.88%
Feb 13, 2025
Maintains: Overweight
Price Target: $415 → $420
Current: $346.33
Upside: +21.27%
Jan 30, 2025
Maintains: Equal-Weight
Price Target: $280 → $240
Current: $192.15
Upside: +24.90%
Jan 23, 2025
Maintains: Buy
Price Target: $285 → $260
Current: $180.26
Upside: +44.24%
Jan 23, 2025
Maintains: Hold
Price Target: $77 → $80
Current: $70.41
Upside: +13.62%
Jan 15, 2025
Upgrades: Equal-Weight
Price Target: $28 → $24
Current: $18.77
Upside: +27.90%
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $85
Current: $54.38
Upside: +56.31%
Aug 27, 2024
Initiates: Overweight
Price Target: $180
Current: $126.68
Upside: +42.09%
Aug 27, 2024
Initiates: Overweight
Price Target: $10
Current: $2.17
Upside: +360.83%
Feb 9, 2024
Downgrades: Hold
Price Target: $30 → $23
Current: $18.68
Upside: +23.13%
Jul 13, 2021
Initiates: Buy
Price Target: $13
Current: $0.74
Upside: +1,652.02%
Nov 2, 2017
Downgrades: Hold
Price Target: n/a
Current: $2.81
Upside: -
Oct 13, 2017
Maintains: Buy
Price Target: $9 → $11
Current: $2.26
Upside: +386.73%